Adropin: Connection between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.
We read the article entitled "Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease." with interest [1]. The authors evaluated serum adropin levels among patients with nonalcoholic fatty liver disease (NAFLD). The authors showed evidence that association of serum levels of adropin with insulin resistance and NAFLD in adult patients. Low serum adropin level is associated with reduced nitric oxide (NO) bioavailability in the endothelium. Reduced NO bioavailability is a major feature of endothelial dysfunction that is predictor of atherosclerosis [2]. Adropin has been identified recently as a regulatory protein that participates in the regulation of energy homeostasis and insulin response [3]. Kumar et al. observed adropin in mice and demonstrated that adropin has protective effects on cardiac system [4]. Ertem et al. investigate the association between non-ST elevation myocardial infarction (NSTEMI) and serum adropin levels [5]. In this study, patients with acute coronary syndrome (ACS) and high SYNTAX score had significantly lower adropin level compared to ACS patients with low SYNTAX score. According to these studies, when the patient diagnosed as NAFLD with low adropin level, further investigations should be considered for detection of coronary artery disease and its complexity.